Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
In a bid to join the billion-dollar sales club, the UK's BTG has snapped up a pair of operations with new delivery tech and a treatment for deep vein thrombosis for up to $420 million—most of that in cash. And it's selling a chunk of shares to help pay for it all.
Add another failure in AstraZeneca's pipeline. The London-based drug giant and partner BTG have scrapped development of an experimental antibody for sepsis and septic shock after mid-stage study bombed, BTG announced today.
The U.K.'s BTG has won FDA approval for Voraxaze, a new treatment designed to lower methotrexate levels. Methotrexate is a commonly used chemo treatment. This new drug is expected to reap about $15
The UK's BTG has announced plans to acquire Biocompatibles for £177 million, or about $242 million. With the acquisition, BTG gains access to Biocompatibles' oncology products, which include
In another pipeline-building move, California's Onyx Pharmaceuticals has shelled out $320 million for BTG's preclinical anticancer compound, BGC 945. BTG gets $13 million up front and could receive
BTG is buying out Protherics for $388 million in a merger deal that will create the UK's biggest biotech company. In the all-stock buyout, Protherics' shareholders will receive 0.291 new BTG shares